KLRS Allovir, Inc.


$ 6.90 $ 0.16 (2.31 %)    

Thursday, 20-Nov-2025 12:17:37 EST
QQQ $ 591.99 $ -19.72 (-3.22 %)
DIA $ 459.22 $ -7.46 (-1.6 %)
SPY $ 657.44 $ -15.53 (-2.31 %)
TLT $ 89.32 $ 0.34 (0.38 %)
GLD $ 372.91 $ -2.34 (-0.62 %)
$ na
$ 6.79
$ 6.99 x 128
$ 7.13 x 100
$ 6.79 - $ 7.09
$ 2.14 - $ 14.63
470,108
na
124.93M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of ...

Core News & Articles

Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform rating ...

Core News & Articles

Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercia...

Core News & Articles

Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION